Vaxcyte Announces FDA Clearance Of Investigational New Drug Application For VAX-31 For Prevention Of Invasive Pneumococcal Disease In Adults
Portfolio Pulse from Benzinga Newsdesk
Vaxcyte has announced that the FDA has cleared its Investigational New Drug application for VAX-31, a drug aimed at preventing invasive pneumococcal disease in adults.
October 19, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxcyte's IND application for VAX-31 has been cleared by the FDA, which could potentially lead to a new product on the market.
The FDA clearance of Vaxcyte's IND application for VAX-31 is a significant step towards the drug's approval and eventual market release. This could potentially lead to increased revenues for the company, thus positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100